TA161 Osteoporosis - secondary prevention including strontium ranelate: review update - August 2012
Review of TA160; Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, TA161; Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, and TA204; Denosumab for the prevention of osteoporotic fractures in postmenopausal women
On 8 August 2012 NICE published the clinical guideline on assessing the risk of fragility fractures in people with osteoporosis. As you are aware, the technology appraisals covering treatments for the prevention of osteoporotic fractures (TA160, TA161, TA204) are to be considered for review when the short clinical guideline on risk assessment has published.
In preparation for a review proposal consultation for TAs 160, 161 and 204, we consider it important to explore how treatment intervention thresholds can be described in a way that aligns them to the assessment of absolute fracture risk. For this we are carrying out a feasibility study through NICE’s Decision Support Unit, and the results of this feasibility study will form part of a formal review proposal. Therefore the consultation of the review proposals for the above technology appraisals has been rescheduled for the autumn of this year.
This page was last updated: 14 August 2012